Sparingvision

Sparingvision company information, Employees & Contact Information

Explore related pages

Related company profiles:

SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause. The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.

Company Details

Employees
47
Founded
-
Address
5-7, Avenue Percier, Paris,île-De-France 75008,france
Phone
+33(0)1 43 46 20 60
Email
in****@****ion.com
Industry
Biotechnology
HQ
Paris, Île-de-France
Looking for a particular Sparingvision employee's phone or email?

Sparingvision Questions

News

SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial - The Manila Times

SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial The Manila Times

Preclinical safety and biodistribution of SPVN06, a novel gene- and mutation-independent gene therapy for rod-cone dystrophies - Nature

Preclinical safety and biodistribution of SPVN06, a novel gene- and mutation-independent gene therapy for rod-cone dystrophies Nature

SparingVision puts faith in Kali Stasi ahead of key trials - The Pharma Letter

SparingVision puts faith in Kali Stasi ahead of key trials The Pharma Letter

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology - Intellia Therapeutics

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Intellia Therapeutics

Daniel Chung swaps SparingVision for Beacon - The Pharma Letter

Daniel Chung swaps SparingVision for Beacon The Pharma Letter

SparingVision announces safety data from first cohort of RP therapy trial - Clinical Trials Arena

SparingVision announces safety data from first cohort of RP therapy trial Clinical Trials Arena

SparingVision shares trial updates for rare eye disease gene therapies - Pharmaceutical Technology

SparingVision shares trial updates for rare eye disease gene therapies Pharmaceutical Technology

SparingVision reaches final dose escalation step in PRODYGY trial with SPVN06 for retinitis pigmentosa - Modern Retina

SparingVision reaches final dose escalation step in PRODYGY trial with SPVN06 for retinitis pigmentosa Modern Retina

Gene therapy in ocular disease spurs excitement with some caution - Healio

Gene therapy in ocular disease spurs excitement with some caution Healio

SparingVision raises €44.5M to develop mutation-agnostic gene therapy - Fierce Biotech

SparingVision raises €44.5M to develop mutation-agnostic gene therapy Fierce Biotech

Intellia looks to eye diseases in latest deal - BioPharma Dive

Intellia looks to eye diseases in latest deal BioPharma Dive

SparingVision’s $75M Raise Represents Optimism For Gene Therapy - Crunchbase News

SparingVision’s $75M Raise Represents Optimism For Gene Therapy Crunchbase News

SparingVision sees to new funding - - Global Venturing

SparingVision sees to new funding - Global Venturing

Longtime biotech VC Jack Nielsen passes away - BioCentury

Longtime biotech VC Jack Nielsen passes away BioCentury

Money on the Move: Sparing Vision, RayzeBio, Nimbus and More Garner Funds - BioSpace

Money on the Move: Sparing Vision, RayzeBio, Nimbus and More Garner Funds BioSpace

Retinitis Pigmentosa Market to Expand Significantly by 2034, States DelveInsight Report | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - The Globe and Mail

Retinitis Pigmentosa Market to Expand Significantly by 2034, States DelveInsight Report | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc The Globe and Mail

Introducing Fierce Biotech's 2023 Fierce 15 - Fierce Biotech

Introducing Fierce Biotech's 2023 Fierce 15 Fierce Biotech

SparingVision raises 75 million euros in Series B financing. - The Pharma Letter

SparingVision raises 75 million euros in Series B financing. The Pharma Letter

Top Sparingvision Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant